- Not Fee assured
- Verified this account
I achieved first class honours at Oxford University and then studied clinical medicine at St Thomas’. Following general medical training in Oxford and London, i obtained a Wellcome Trust Research Fellowship at the Royal Free Hospital which led to a doctoral thesis at Oxford University. I completed training in haematology through rotations at St Thomas’, St George’s and the Royal Marsden Hospital, London before taking up my current post at University Hospital Southampton in 1994. I have practiced at Spire Southampton since 2001. As lead consultant in clinical haematology from 1995 to 2001.
I have been involved in extensive research into myeloproliferative disorders (disorders of the blood cells). As a core member of the National Cancer Research Institute's myeloproliferative disorders subgroup, I have co-authored national guidelines for the management and treatment of the conditions myelofibrosis and eosinophilia. I have been involved in research with patients with myelofibrosis which has led to the discovery of gene mutations that help to explain why some people are predisposed to acquiring genetic mutations that lead to blood cancers.
I am also highly experienced in lymphoid as well as myeloid blood cancers and involved in clinical trials in these disorders.
I have authored more than 100 original articles and published abstracts including first author publications in the New England Journal of Medicine, Lancet and British Medical Journal. I co-authored the first edition of the Oxford Handbook of Clinical Haematology, and contributed entries on this topic to the British Medical Association Family Health Encyclopedia, which went on to become an international bestseller. While on sabbatical in 2016, i was a visiting guest lecturer at the University of Western Australia, Perth, University of New South Wales, Sydney, University of Otago, NZ and University of Auckland, NZ.
Until my recent retirement from the NHS, I was a National Clinical Excellence Award Holder.
Areas of interest
Myeloproliferative disorders including Polycythaemia, Myelofibrosis, Thrombocythaemia;
Lymphoproliferative disorders including chronic lymphocytic leukaemia; Myelodysplasia; Chronic Myeloid Leukaemia.
Current NHS consultant posts held
Consultant Haematologist and Honorary Senior Lecturer in Haematology,
University Hospital Southampton
Dr Duncombe is committed to advancing patient outcomes through promotion of and involvement in research, both clinical trials and laboratory studies. He has been an investigator in more than 40 National Cancer Research Institute studies.
Dr Duncombe is the author of more than 100 original articles and published abstracts including first author publications in the New England Journal of Medicine, Lancet, British Medical Journal, BLOOD, Journal of Immunology and the British Journal of Haematology. He co-authored the first edition of the Oxford Handbook of Clinical Haematology, and contributed entries on this topic to the British Medical Association Family Health Encyclopedia, which went on to become an international bestseller.
Outside of work, Dr Duncombe enjoys spending time with his family, walking in the New Forest and singing in an acapella group. He likes playing tennis and watching rugby, football, hockey and cricket.
First class honours in physiological sciences from Oxford University, 1978
University scholarship to St Thomas' Hospital, 1978
Martin Wronker prize in pharmacology, Oxford, 1978
British Society For Haematology Young Investigator Of The Year, 1988/1989
Wellcome Trust research fellowship, 1987 to 1990
National Clinical Excellence Award holder, 2015- Retirement from NHS Pension scheme.
Guglielmelli P, Lasho TL, Rotunno G, Score J, Mannarelli C, Pancrazzi A, Biamonte F, Pardanani A Zoi K, Reiter A, Duncombe A , Fanelli T, Pietra D, Rumi E, Finke C, Gangat C, Ketterling RP, Knudson RA, Hanson CA, Bosi A, Pereira A, Manfredini R, Cervantes F, Barosi G, Cazzola M, Cross NCP, Vannucchi AM, Tefferi A. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients, Leukemia. 2014 Sep;28(9):1804-10.
Titmarsh GJ, Duncombe AS, McMullin MF, O’Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA. How common are myeloproliferative neoplasms? A systematic review and meta-analysis, Am J Hematol. 2014 Jun;89(6):581-7.
Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, Cook SJ, Stevenson FK, Packham G. Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukaemia. Blood. 2012 Feb 16;119(7):1726-36.
Guglielmelli P, Biamonte F, Score J, Hidalgo-Curtis C, Cervantes F, Maffioli M, Fanelli T, Ernst T, Winkelman N, Jones AV, Zoi K, Reiter A, Duncombe A, Villani L, Bosi A, Barosi G, Cross NC, Vannucchi AM. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011 Nov 10;118(19):5227-34.
Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A, Hochhaus A, Drexler HG, Duncombe A, Cervantes F, Oscier D, Boultwood J, Grand FH, Cross NC. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics. 2010 Aug;42(8):722-6.
Provan A B, Chisholm D M, Duncombe A S, Singer C, Smith A G. Oxford Handbook of Clinical Haematology, Oxford University Press, 1998 [ISBN 0 19 262903 4].
Duncombe A S, Blood and marrow stem cell transplantation. Chapter 12 of ABC of Clinical Haematology 2nd edition, BMJ Books, London, 2003 [ISBN 0 7279 16769].
Duncombe A S, Haematological entries in The British Medical Association Complete Family Health Encyclopedia, Dorling Kindersley Publications, London, 1990.
Duncombe A S, Expert on BBC RADIO 4 CASENOTES in 1999 (peripheral blood stem cell transplantation) and 2001 (the lymphatic system).
Courses offered to GPs
Updates to GPs organised by Spire Southampton
- MB BS London 1981
- MA Oxford University 1982
- DM Oxford University 1991
- FRCP Royal College of Physicians 1999
- FRCPath Royal College of Pathologists 2000
Reference number 2722339
Professional bodies (positions held - last 3 yrs)
- HaemOnc subgroup member NCRI 2008
Details of entry to specialist register
- Haematology, 1994
- Chalybeate CloseSOUTHAMPTONSO16 6UY
- 16:00 - 19:00
- 023 8076 4320
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
02380 775544 and ask for Senior Oncology Nurse on call